February 12, 2018
Annual Award Recognizes the Most Significant Contributor to Canada’s Innovative Healthcare Industry
TORONTO, February 12, 2018 - Bloom Burton & Co. (“Bloom Burton”) is thrilled to announce the 2018 Bloom Burton Award Gala, to be held at the Four Seasons Hotel in Toronto, Ontario, Canada on Thursday, September 27, 2018.
Bestowed annually, the Bloom Burton Award honours an individual scientist, inventor, executive, entrepreneur, industry leader, or policy maker who made the greatest contribution to Canada’s innovative healthcare industry in the previous year. Nominees will be accepted from any of the biotechnology, pharmaceutical, medical device, diagnostic/imaging, research instrumentation, consumer health, services or healthcare IT sectors, and equal consideration will be given to contributions across any stage of development – from discovery to commercial end markets. The Bloom Burton Award recognizes the individual for their specific, significant contribution from the previous year.
The Bloom Burton Award winner will be chosen from an esteemed panel of judges, all of whom are respected international leaders in healthcare investment, entrepreneurship and journalism:
Nominations may be submitted by the public at large on or before April 15, 2018. A narrowed list of three finalists will be announced at the Bloom Burton & Co. Healthcare Investor Conference, May 2-3, 2018. All three finalists, along with their family and friends, will be invited to and celebrated at the Bloom Burton Award Gala on September 27, 2018. Each of the three finalists will receive a $25,000 cash prize, and a single winner will receive the 2018 Bloom Burton Award. A limited number of tickets are available for industry sponsors and individuals; please visit www.bloomburton.com for more information. Brian Bloom, Chairman and CEO of Bloom Burton commented, “It is a rare opportunity to bring together, focus on and celebrate those innovators who advance medical science, attract or provide risk capital, launch new products and companies on the world stage and bring about positive impacts on society. The Bloom Burton Award cherishes today’s finest contributors to Canada’s innovative healthcare industry for their specific achievement from the previous year.” Kindly send single page nomination letters to: Eleanor Ndaiga Tel: (416) 640-7573 endaiga@bloomburton.com For table sponsorship and other inquiries: Brian Bloom Chairman & CEO Tel: (416) 640-7580 bbloom@bloomburton.com About Bloom Burton & Co.: Bloom Burton & Co. (Bloom Burton Securities Inc.) is a firm dedicated to accelerating returns in the healthcare sector for both investors and companies. Bloom Burton has an experienced team of medical, scientific, pharmaceutical, legal and capital markets professionals who perform a deep level of diligence, which combined with our creative and entrepreneurial approach, assists our clients in achieving the right monetization events. Bloom Burton and its affiliates provide capital raising, M&A advisory, equity research, business strategy and scientific consulting, advisory on direct investing and company creation and incubation services. Bloom Burton Securities Inc. is a member of the Investment Industry Regulatory Organization of Canada (IIROC) and is also a member of the Canadian Investor Protection Fund (CIPF). Please visit www.bloomburton.com to learn more.
<
>
Canada in Science - November 9, 2018
America's Midwestern Gem: How Chicago is Building the Next Biomedical Research Hub
Canada in Science - September 7, 2018
Q2 2018 Share Price Performance
Canada in Science - August 3, 2018
Canada in Science - July 6, 2018
Greenbrook TMS Announces Closing of Private Placement Totaling USD $20,000,000
Canada in Science - June 7, 2018
CannTrust™ Announces Closing of $100,395,000 Bought Deal
Bloom Burton & Co. Welcomes Michael J. Brown, CFA® as Portfolio Manager and Chief Executive Officer of its Asset Management Affiliate, Bloom Burton Investment Group.
Q1 2018 Share Price Performance
From Motor City to Health Innovation City? Detroit's Unexpected Comeback
Kneat Announces Closing of $6.185 Million Brokered Private Placement
Canada in Science - April 6, 2018
Sunniva Inc. Closes $27.8 Million Bought Deal Public Offering
Immunovaccine Announces Closing of CAD$14,375,000 Bought Deal Offering with Over-Allotment Option Exercised in Full
Canada in Science - March 2, 2018
Big Pharma's Drug War: Innovative vs. Generic and Biosimilar Drugs
Bloom Burton & Co. Announces the 2018 Bloom Burton Award Gala
Canada in Science - Feb 2, 2018
Plasma for Profit: The Changing Landscape of Blood Donation
Q4 & Annual 2017 Share Price Performance - Part 3
Q4 & Annual 2017 Share Price Performance - Part 2
ESSA Completes US$26 Million Equity Offering
Paul Lammers, M.D., M.Sc. Joins Triumvira as President and Chief Executive Officer
Q4 Share Price Performance in 2017 - Part 1
BELLUS Health Closes $20M Common Share Financing
Canada in Science - December 1, 2017
Avivagen Announces Closing of Private Placement Totaling $4,000,000
CannTrust™ Announces Closing of $20,000,000 Bought Deal
The Emergence of the HIV/AIDS Epidemic and How it Affected the Human Plasma Industry
Q3 Share Price Performance in 2017 - Part 3
Q3 Share Price Performance in 2017 - Part 2
Q3 Share Price Performance in 2017 - Part 1
Canada in Science - November 3, 2017
Acquisitions in the Life Sciences Start-Up Space: A Principal-Agent Problem in the Making
Appili Therapeutics Receives FDA and Health Canada Clearance to Begin Clinical Trials on ATI-1501